Cipher Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CPHRF research report →
Companywww.cipherpharma.com
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug.
- CEO
- Craig J. Mull
- IPO
- 2006
- Employees
- 6
- HQ
- Mississauga, ON, CA
Price Chart
Valuation
- Market Cap
- $316.01M
- P/E
- 10.05
- P/S
- 6.11
- P/B
- 2.34
- EV/EBITDA
- 12.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 74.53%
- Op Margin
- 38.76%
- Net Margin
- 60.82%
- ROE
- 25.69%
- ROIC
- 14.81%
Growth & Income
- Revenue
- $51.33M · 53.87%
- Net Income
- $27.81M · 140.86%
- EPS
- $1.09 · 131.91%
- Op Income
- $16.80M
- FCF YoY
- 54.95%
Performance & Tape
- 52W High
- $15.00
- 52W Low
- $8.54
- 50D MA
- $12.92
- 200D MA
- $11.29
- Beta
- -0.16
- Avg Volume
- 5.12K
Get TickerSpark's AI analysis on CPHRF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CPHRF Coverage
We haven't published any research on CPHRF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CPHRF Report →